1Deschenes G,Doucet A. Collecting Duct Na^+/K^+ - ATPase Activity is correlated with urinary sodium excretion in rat nephrotic syndromes. J Am Soc Nephrol,2000,11 (4) :604 - 615.
2Venkatesan N, Punithavathi D, Arumugam V. Curcurnin prevents adriamycin nephrotoxicity in rats. Br J Pharmacol, 2000, 129(2) :231 - 234.
3De Boer ED, Navis G, Tiebosch ATM, et al. Systemic factors are involved in the pathogenesis of proteinuriainduced glomemlosclerosis in adriamycin nephrotic rats. J Am Soc Nephrol, 1999,10(11) :2359 - 2366.
4Cheng HF,Wang S, Jo YI, et al. Overexpression of cyclooxygenase-2 predisposes to podocyte injury. J Am Soc Nephrol, 2007,18(2) :551 - 559.
5Fogo AB. Animal models of FSGS: lessons for pathogenesis and treatment. Semin Nephrol,2003,23(2) :161 171.
6Zheng ZY, Schmidt - Ott KM, Chua S, et at. A Mendelian locus on chromosome 16 determines susceptibility to doxorubicin nephropathy in the mouse. Proc Natl Acad Sci USA, 2005, 102 (7) :2502 - 2507.
7Wang Y, Wang YP, Tay YC, et al.Progressive adriamydn nephropathy in mice: Sequence of histologic and immunohistcchemical events. Kidney Int,2000,58(4) : 1797 - 1804.
8Mahajan D, Wang YP, Qin XH, et al. CD4^+ CD25^+ regulatory T cells protect against injury in an innate murine model of chronic kidney disease. J Am Soc Nephrol,2006,17(10) :2731 2741.
10Takamura N, Maruyama T, Chosa E, et al. Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furctsemide: potential for use of Bucolome to restore diuretic response in nephrotic syndrome. Drug Metab Dispos, 2005,33 (4) : 596 - 602.
